ArticleCytotherapy2016
Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes.
Article in Cytotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial.Nature medicine · 2023Trial
- Peptides targeting RAB11A-FIP2 complex inhibit HPIV3, RSV, and IAV replication as broad-spectrum antivirals.Cell & bioscience · 2025Article
- Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease.Blood advances · 2023Article
- Pathogen-specific T Cells: Targeting Old Enemies and New Invaders in Transplantation and Beyond.HemaSphere · 2023Review
- Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific T cell therapy products.Molecular therapy. Methods & clinical development · 2022Article
- Article
- Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies.Cytotherapy · 2020Review
- Review
- T-Cell Therapeutics Targeting Human Parainfluenza Virus 3 Are Broadly Epitope Specific and Are Cross Reactive With Human Parainfluenza Virus 1.Frontiers in immunology · 2020Article
- The pipeline of antiviral T-cell therapy: what's in the clinic and undergoing development.Transfusion · 2020Review
- RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.Clinical transplantation · 2019Article
- Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients.Blood advances · 2019Article
- Virus-Specific T Cells: Current and Future Use in Primary Immunodeficiency Disorders.The journal of allergy and clinical immunology. In practice · 2019Review
- Infusion of cytotoxic T lymphocytes for the treatment of viral infections in hematopoetic stem cell transplant patients.Current opinion in infectious diseases · 2018Review
- A New Method for Reactivating and Expanding T Cells Specific forMolecular therapy. Methods & clinical development · 2018Article
- Human papilloma virus-specific T cells can be generated from naïve T cells for use as an immunotherapeutic strategy for immunocompromised patients.Cytotherapy · 2018Article
- Respiratory Virus Infections in Hematopoietic Cell Transplant Recipients.Frontiers in microbiology · 2018Review
- Respiratory Viral Infections in Solid Organ and Hematopoietic Stem Cell Transplantation.Clinics in chest medicine · 2017Review
- Update in the treatment of non-influenza respiratory virus infection in solid organ transplant recipients.Expert opinion on pharmacotherapy · 2017Review
- Adoptive T Cell Immunotherapy for Patients with Primary Immunodeficiency Disorders.Current allergy and asthma reports · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
BACKGROUND
aimsHuman parainfluenza virus-3 (HPIV) is a common cause of respiratory infection in immunocompromised patients and currently has no effective therapies. Virus-specific T-cell therapy has been successful for the treatment or prevention of viral infections in immunocompromised patients but requires determination of T-cell antigens on targeted viruses.
methodsHPIV3-specific T cells were expanded from peripheral blood of healthy donors using a rapid generation protocol targeting four HPIV3 proteins. Immunophenotyping was performed by flow cytometry. Viral specificity was determined by interferon (IFN)-γ ELISpot, intracellular cytokine staining and cytokine measurements from culture supernatants by Luminex assay. Cytotoxic activity was tested by
resultsHPIV3-specific T cells were expanded from 13 healthy donors. HPIV3-specific T cells showed a CD4 DISCUSSION: HPIV3-specific T cells can be produced using a rapid ex vivo protocol from healthy donors and are predominantly CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.